Table Graph
      published meta-analysis   sensitivity analysis   studies

Comirnaty (tozinameran - Pfizer/BIONTECH) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsArbel, 2021 (REV) 10.00 [7.07; 14.14] Barda, 2021 (REV) 5.26 [1.42; 19.46] 9.59[6.86; 13.40]Arbel, 2021 (REV), Barda, 2021 (REV)20%843,208seriousnot evaluable hospitalization or deathdetailed resultsAbu-Raddad, 2022 (REV) 4.35 [2.27; 8.33] 4.35[2.27; 8.33]Abu-Raddad, 2022 (REV)10%NAnot evaluable confirmed COVID (any severity)detailed resultsAbu-Raddad, 2022 (REV) 1.96 [1.87; 2.06] Bar-On, 2021 (REV) 11.36 [10.04; 12.87] C4591031- first boost, 2021 (REV) 18.52 [7.91; 43.34] 18.52[7.91; 43.34]Abu-Raddad, 2022 (REV), Bar-On, 2021 (REV), C4591031- first boost, 2021 (REV)10%10,125NAnot evaluable hospitalizationdetailed resultsBarda, 2021 (REV) 14.29 [7.14; 28.57] Botton (EPI-PHARE), 2022 (REV) 0.15 [0.10; 0.22] Patalon, 2022 (REV) 12.50 [7.75; 20.16] Tan, 2022 (REV) 21.28 [11.84; 38.24] 4.85[0.33; 71.80]Barda, 2021 (REV), Botton (EPI-PHARE), 2022 (REV), Patalon, 2022 (REV), Tan, 2022 (REV)499%NAnot evaluable symptomatic Covid-19detailed resultsAbu-Raddad, 2022 (REV) 1.96 [1.87; 2.06] COVI3, 2022 (REV) 14.29 [4.04; 50.51] 4.77[0.69; 33.03]Abu-Raddad, 2022 (REV), COVI3, 2022 (REV)289%NAnot evaluable severe COVID-19 (FDA definition)detailed resultsC4591031- first boost, 2021 (REV) 4.03 [0.18; 89.41] 4.03[0.18; 89.41]C4591031- first boost, 2021 (REV)10%10,125NAnot evaluable severe COVID-19 occurrencedetailed resultsBar-On, 2021 (REV) 15.38 [10.47; 22.61] Barda, 2021 (REV) 12.50 [5.10; 30.62] C4591031- first boost, 2021 (REV) 4.03 [0.18; 89.41] 4.03[0.18; 89.41]Bar-On, 2021 (REV), Barda, 2021 (REV), C4591031- first boost, 2021 (REV)10%10,125NAnot evaluable adverse eventsdetailed resultsCom-COV, 2021 (REV) 0.88 [0.60; 1.28] 0.88[0.60; 1.28]Com-COV, 2021 (REV)10%463NAnot evaluable arrhythmiadetailed resultsC4591031- first boost, 2021 (REV) 0.50 [0.02; 15.01] 0.50[0.02; 15.01]C4591031- first boost, 2021 (REV)10%10,075NAnot evaluable hypertensiondetailed resultsC4591031- first boost, 2021 (REV) 2.01 [0.07; 60.05] 2.01[0.07; 60.05]C4591031- first boost, 2021 (REV)10%10,075NAnot evaluable intracranial hemorrhage detailed resultsCom-COV, 2021 (REV) 0.99 [0.02; 49.96] 0.99[0.02; 49.96]Com-COV, 2021 (REV)10%463NAnot evaluable ischemic strokedetailed resultsCom-COV, 2021 (REV) 0.99 [0.02; 49.96] 0.99[0.02; 49.96]Com-COV, 2021 (REV)10%463NAnot evaluable Myocardial infarction detailed resultsC4591031- first boost, 2021 (REV) 1.34 [0.30; 6.00] Com-COV, 2021 (REV) 0.99 [0.02; 49.96] Reindl-Schwaighofer, 2021 (REV) 0.49 [0.02; 14.85] 1.34[0.30; 6.00]C4591031- first boost, 2021 (REV), Com-COV, 2021 (REV), Reindl-Schwaighofer, 2021 (REV)10%10,075NAnot evaluable pulmonary embolismdetailed resultsC4591031- first boost, 2021 (REV) 6.04 [0.30; 120.71] Com-COV, 2021 (REV) 0.99 [0.02; 49.96] 6.04[0.30; 120.71]C4591031- first boost, 2021 (REV), Com-COV, 2021 (REV)10%10,075NAnot evaluable serious adverse events (SAE), anydetailed resultsReindl-Schwaighofer, 2021 (REV) 0.65 [0.11; 4.00] 0.65[0.11; 4.00]Reindl-Schwaighofer, 2021 (REV)10%201NAnot evaluable stroke (non-specific, hemorrhagic, and ischemic)detailed resultsC4591031- first boost, 2021 (REV) 1.01 [0.06; 16.10] 1.01[0.06; 16.10]C4591031- first boost, 2021 (REV)10%10,075NAnot evaluable venous thromboembolism detailed resultsReindl-Schwaighofer, 2021 (REV) 0.49 [0.02; 14.85] 0.49[0.02; 14.85]Reindl-Schwaighofer, 2021 (REV)10%201NAnot evaluable cerebral venous sinus thrombosis (CVST)detailed resultsC4591031- first boost, 2021 (REV) 2.01 [0.07; 60.05] 2.01[0.07; 60.05]C4591031- first boost, 2021 (REV)10%10,075NAnot evaluable appendicitisdetailed resultsC4591031- first boost, 2021 (REV) 0.25 [0.01; 5.58] 0.25[0.01; 5.58]C4591031- first boost, 2021 (REV)10%10,075NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-07-08 06:38 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 758 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons